Drug intelligence / Profile preview

PVT-005

Development stage: Preclinical
Lead developer: Pivot Pharmaceuticals
Modality: Small Molecules

Overview

PVT-005 is a preclinical small molecule anticancer drug candidate. It was part of a pipeline developed by IndUS Pharmaceuticals, which was acquired by Pivot Pharmaceuticals in 2015. The drug is designed to target refractory women's cancers, specifically metastatic endometrial cancer and basal-like-triple-negative breast cancer. Its mechanism of action is based on PBD dimers, which are known DNA alkylating agents.

Targets

DNA

Beyond the preview

Go deeper on PVT-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PVT-005.

Explore the full profile